Related MeSH Hierarchy (4)
Diseases [C] » Nervous System Diseases [C10] » Neurologic Manifestations » Neurobehavioral Manifestations » Confusion » Delirium
Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Signs and Symptoms » Neurologic Manifestations » Neurobehavioral Manifestations » Confusion » Delirium
Psychiatry and Psychology [F] » Behavior and Behavior Mechanisms [F01] » Neurobehavioral Manifestations » Confusion » Delirium
Psychiatry and Psychology [F] » Mental Disorders [F03] » Neurocognitive Disorders » Delirium
Description
A disorder characterized by CONFUSION; inattentiveness; disorientation; ILLUSIONS; HALLUCINATIONS; agitation; and in some instances autonomic nervous system overactivity. It may result from toxic/metabolic conditions or structural brain lesions. (From Adams et al., Principles of Neurology, 6th ed, pp411-2) MeSH
Hierarchy View
Subtype Terms (1)
Emergence Delirium
27 drugs (23 approved, 4 experimental)
Phase 4 Indicated Drugs (38)
Phase 2 Indicated Drugs (8)
Organization Involved with Phase 4 Indications (133)
Anhui College of Traditional Chinese Medicine
Centro Medico Nacional La Raza, IMSS
Chinese Academy of Medical Sciences
Chinese University of Hong Kong
Huazhong University of Science and Technology
Icahn School of Medicine at Mount Sinai
Instituto de Medicina Integral Professor Fernando Figueira
Memorial Health University Medical Center
Methodist Rehabilitation Center
Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy
Moscow Regional Research Clinical Institute
National Institute on Aging (NIA)
National Institutes of Health (NIH)
People's Liberation Army of China
Postgraduate Institute of Medical Education and Research
Rebeca Gonelli Albanez da Cunha Andrade
Scandinavian Critical Care Trials Group
Second Military Medical University
Shaanxi Provincial People's Hospital
Shandong Province Qianfoshan Hospital
State University of New York, Buffalo
The Danish Centre of Applied Social Science
The University of Texas, Dallas
Organization Involved with Phase 3 Indications (45)
Assistance Publique - Hôpitaux de Paris
Grupo Español de Rehabilitación Multimodal
Instituto de Estudios de Ciencias de la Salud de Castilla y León (IECSCYL)
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
Organization Involved with Phase 2 Indications (17)
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (32)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
